PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMinoxidil
Minoxidil
Minoxidil, Rogaine, Theroxidil (minoxidil) is a small molecule pharmaceutical. Minoxidil was first approved as Loniten on 1982-01-01. It is used to treat alopecia and malignant hypertension in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Minoxidil, Rogaine (discontinued: Loniten, Minoxidil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Minoxidil
Tradename
Company
Number
Date
Products
ROGAINE (FOR MEN)Johnson & JohnsonN-019501 OTC1996-02-09
1 products, RLD, RS
ROGAINE (FOR WOMEN)Johnson & JohnsonN-019501 OTC1996-02-09
1 products, RLD, RS
ROGAINE EXTRA STRENGTH (FOR MEN)Johnson & JohnsonN-020834 OTC1997-11-14
1 products, RLD, RS
MEN'S ROGAINEJohnson & JohnsonN-021812 OTC2006-01-20
1 products, RLD, RS
WOMEN'S ROGAINEJohnson & JohnsonN-021812 OTC2014-02-28
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
10%de minoxidilC2002632024-11-04
2% minoxidil hair growth oilANDA2023-11-02
2% minoxidil hair growth serumC2002632024-08-30
2% minoxidil hair regrowth serumANDA2023-10-11
2% women minoxidil hair strengthening setC2002632024-07-30
3rx minoxidil hair regrowth treatment for menunapproved drug other2024-06-18
5 minoxidil hair foam with biotinC2002632024-10-14
5% men minoxidil hair strengthening setC2002632024-07-30
5% minoxidilC2002632024-09-09
5% minoxidil foamC2002632024-09-12
Show 267 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
alopeciaHP_0002293D000505L64
malignant hypertensionEFO_1001031D006974—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DC: Pyrimidine derivatives acting on arteriolar smooth muscle
— C02DC01: Minoxidil
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX01: Minoxidil
HCPCS
Code
Description
S0139
Minoxidil, 10 mg
Clinical
Clinical Trials
80 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlopeciaD000505HP_0002293L6412191671662
Alopecia areataD000506EFO_0004192L6311171671559
HypotrichosisD007039HP_0008070—1——2—3
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N08——1——1
Polycystic kidney diseasesD007690HP_0000113Q61.3——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420—T88.711———1
Self-assessmentD012647——11———1
SyndromeD013577———1———1
Williams syndromeD018980Orphanet_904Q93.82—1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Ovarian epithelial carcinomaD000077216———1———1
Acne vulgarisD000152EFO_0003894L7011———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501————1
Healthy volunteers/patients———1————1
PharmacokineticsD010599——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10————33
Covid-19D000086382——————11
Fissure in anoD005401HP_0012390K60.2————11
Wounds and injuriesD014947—T14.8————11
Wound healingD014945GO_0042060—————11
Premature birthD047928EFO_0003917O60————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMinoxidil
INNminoxidil
Description
Minoxidil is a pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6. It has a role as a vasodilator agent and an antihypertensive agent. It is a pyrimidine N-oxide, a member of piperidines and an aminopyrimidine.
Classification
Small molecule
Drug classvasodilators (undefined group)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1cc(N2CCCCC2)nc(N)[n+]1[O-]
Identifiers
PDB—
CAS-ID38304-91-5
RxCUI—
ChEMBL IDCHEMBL802
ChEBI ID6942
PubChem CID4201
DrugBankDB00350
UNII ID5965120SH1 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Minoxidil
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,489 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
55,874 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use